Get the Stockscreener App
0.5444
6.41%
-0.0373
Atyr Pharma Inc stock is traded at $0.5444, with a volume of 1.37M.
It is down -6.41% in the last 24 hours and up +16.23% over the past month.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).
See More
Previous Close:
$0.5817
Open:
$0.5801
24h Volume:
1.37M
Relative Volume:
0.55
Market Cap:
$53.38M
Revenue:
$190.00K
Net Income/Loss:
$-70.03M
P/E Ratio:
-0.7414
EPS:
-0.7343
Net Cash Flow:
$-59.30M
1W Performance:
-8.12%
1M Performance:
+16.23%
6M Performance:
-23.61%
1Y Performance:
-89.79%
1-Day Range:
$0.535
$0.5899
1-Week Range:
$0.535
$0.6998
52-Week Range:
$0.395
$7.2904
Atyr Pharma Inc Stock (ATYR) Company Profile
Name
Atyr Pharma Inc
Sector
Industry
Phone
(858) 731-8389
Address
10240 SORRENTO VALLEY ROAD, SAN DIEGO
Compare ATYR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATYR
Atyr Pharma Inc
|
0.5444 | 53.38M | 190.00K | -70.03M | -59.30M | -0.7343 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-16-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-15-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-15-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-18-25 | Initiated | Leerink Partners | Outperform |
| Jan-06-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-04-24 | Initiated | Wells Fargo | Overweight |
| Sep-05-24 | Initiated | Jefferies | Buy |
| Jul-05-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Oct-12-21 | Initiated | RBC Capital Mkts | Outperform |
| Sep-21-21 | Initiated | Piper Sandler | Overweight |
| May-10-21 | Initiated | Laidlaw | Buy |
| Aug-17-20 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Mar-04-20 | Initiated | ROTH Capital | Buy |
| Mar-02-20 | Initiated | Oppenheimer | Outperform |
| Feb-14-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-07-17 | Initiated | Piper Jaffray | Overweight |
| Dec-13-16 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-16-15 | Initiated | Citigroup | Neutral |
| Jun-01-15 | Initiated | Citigroup | Buy |
| Jun-01-15 | Initiated | JP Morgan | Overweight |
View All
Atyr Pharma Inc Stock (ATYR) Latest News
aTyr Pharma(ATYR) Stock Options Chain | Quotes & News - Moomoo
aTyr Pharma Company Profile & Introduction - Moomoo
aTyr Pharma (ATYR) Stock Forecast & Analyst Ratings - Moomoo
Federated Hermes (NASDAQ: ATYR) amends 13G, reports 8.51M shares - Stock Titan
aTyr Pharma, Inc. Actuals & Estimates (HAM:471A) - TradingView
aTyr Pharma updates its pipeline strategy as LIFE advances clinical programs - ad-hoc-news.de
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds - The National Law Review
What triggered aTyr Pharma shares' latest price surge - Traders Union
JonesTrading Maintains ATyr Pharma(ATYR.US) With Hold Rating - Moomoo
aTyr Pharma Inc (LIFE) News Today: Latest Market and Industry Updates - Traders Union
Buying pressure lifts aTyr Pharma stock higher in today's trading - Traders Union
Price to book forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Enterprise value to EBIT forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Enterprise value to revenue forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Enterprise value to EBITDA forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Price to earnings forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Price to sales forward of aTyr Pharma, Inc. – NASDAQ:ATYR - TradingView
Class Action Filed Against aTyr Pharma, Inc. (ATYR) Over Securities ViolationsContact Levi & Korsinsky Today - The National Law Review
ATYR SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
Join Class Action to Recover Losses from aTyr Pharma, Inc. (ATYR) - The National Law Review
ATYR STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
ATYR INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Class Action Alert: Levi & Korsinsky Reminds aTyr (ATYR) Investors of December 8, 2025 Deadline - The National Law Review
Recover Investment Losses: Class Action Initiated Against aTyr Pharma, Inc. (ATYR) - The National Law Review
Levi & Korsinsky Urges aTyr Pharma, Inc. (ATYR) Shareholders to Act Before Lead Plaintiff Deadline December 8, 2025 - The National Law Review
Levi & Korsinsky Moves to SueWallSt For aTyr Pharma, Inc. Investors That Lost Money - The National Law Review
Burned by aTyr Pharma, Inc.? Contact Levi & Korsinsky to SueWallSt And Fight Back - The National Law Review
Shareholders SueWallSt in New Class Action Against aTyr Pharma, Inc.Act Now - The National Law Review
Investors Urged to Contact Levi & Korsinsky for Information Before December 8, 2025aTyr Pharma, Inc. (ATYR) - The National Law Review
Investors in aTyr Pharma, Inc. (ATYR): Protect Your RightsContact Levi & Korsinsky Before December 8, 2025 - The National Law Review
Investors SueWallSt Over aTyr Pharma, Inc. Stock DropContact Levi & Korsinsky to Join - The National Law Review
Securities Lawsuit Alert: aTyr Pharma, Inc. (ATYR)Contact Levi & Korsinsky Before December 8, 2025 - The National Law Review
ATYR Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
aTyr Pharma (ATYR) Revenue BreakdownMain Composition - Moomoo
aTyr Pharma, Inc. Actuals & Estimates (NASDAQ:ATYR) - TradingView
ATYR Forecast — Price Target — Prediction for 2027 - TradingView
aTyr Pharma Ord Shs (LIFE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
aTyr Pharma Inc (ATYR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
aTyr Pharma StockLong-term strategy and pipeline focus - AD HOC NEWS
ATYR News | ATYR PHARMA INC (NASDAQ:ATYR) - ChartMill
aTyr Pharma Ord Shs (LIFE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
aTyr Pharma Ord Shs (LIFE) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
aTyr Pharma Inc (ATYR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
aTyr Pharma Inc (ATYR) Institutional Confidence - TradingKey
aTyr Pharma Inc (ATYR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
aTyr Pharma Inc (ATYR) Valuation: PE, PB & Fair Value Analysis - TradingKey
aTyr Pharma Inc (ATYR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
aTyr Pharma Inc (ATYR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
aTyr Pharma Inc (ATYR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
FMR LLC Significantly Reduces Holdings in aTyr Pharma Inc - GuruFocus
Atyr Pharma Inc Stock (ATYR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atyr Pharma Inc Stock (ATYR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shukla Sanjay | President and CEO |
Feb 04 '26 |
Sale |
0.98 |
3,745 |
3,655 |
153,553 |
| Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '26 |
Sale |
0.98 |
1,558 |
1,521 |
37,296 |
| DENYES NANCY | General Counsel |
Feb 04 '26 |
Sale |
0.98 |
1,118 |
1,091 |
33,124 |
| SCHIMMEL PAUL | Director |
Oct 08 '25 |
Buy |
0.90 |
682,001 |
612,437 |
1,095,024 |
| SCHIMMEL PAUL | Director |
Oct 09 '25 |
Buy |
0.94 |
317,999 |
299,364 |
1,413,023 |
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):